-
1
-
-
33747122666
-
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
-
Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006,296:827-843.
-
(2006)
JAMA
, vol.296
, pp. 827-843
-
-
Hammer, S.M.1
Saag, M.S.2
Schechter, M.3
-
2
-
-
0035958773
-
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
-
Bartlett J, DeMasi R, Quinn J, Moxham C, Rousseau, F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15(11):1369-1377.
-
(2001)
AIDS
, vol.15
, Issue.11
, pp. 1369-1377
-
-
Bartlett, J.1
DeMasi, R.2
Quinn, J.3
Moxham, C.4
Rousseau, F.5
-
3
-
-
84858101786
-
-
US Department of Health and Human Services, Available at:, Accessed May
-
US Department of Health and Human Services. Darunavir prescribing information. Available at: www.aidsinfo.nih. gov. Accessed May 2007.
-
(2007)
Darunavir prescribing information
-
-
-
4
-
-
19544386471
-
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
-
De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-2321.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 2314-2321
-
-
De Meyer, S.1
Azijn, H.2
Surleraux, D.3
-
5
-
-
20644450806
-
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: A 14-day proof of principle trial
-
Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof of principle trial. AIDS. 2005;19:943-947.
-
(2005)
AIDS
, vol.19
, pp. 943-947
-
-
Arasteh, K.1
Clumeck, N.2
Pozniak, A.3
-
6
-
-
34547186809
-
-
Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, Massachusetts, USA. Abstract 164LB.
-
Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, Massachusetts, USA. Abstract 164LB.
-
-
-
-
7
-
-
34547203224
-
-
Katlama C, Carvalho M, Cooper D, et al. POWER 1 (TMC-114-C213 Study) week 24 analysis. In: Program and abstracts of the Third IAS Conference on HIV Pathogenesis; July 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102.
-
Katlama C, Carvalho M, Cooper D, et al. POWER 1 (TMC-114-C213 Study) week 24 analysis. In: Program and abstracts of the Third IAS Conference on HIV Pathogenesis; July 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102.
-
-
-
-
8
-
-
34547181045
-
POWER 2 (TMC114-202 study). Week 24 Efficacy analysis
-
December, Washington, DC, USA. Abstract H-1094
-
Wilkin T, Haubrich R, Steinhart C, et al. POWER 2 (TMC114-202 study). Week 24 Efficacy analysis. In: Program and abstracts of ICAAC; December 2005; Washington, DC, USA. Abstract H-1094.
-
(2005)
Program and abstracts of ICAAC
-
-
Wilkin, T.1
Haubrich, R.2
Steinhart, C.3
-
10
-
-
22444439664
-
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
-
Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
-
(2005)
AIDS
, vol.19
, pp. 685-694
-
-
Johnson, M.1
Grinsztejn, B.2
Rodriguez, C.3
-
12
-
-
29844453324
-
Tipranavir: A protease inhibitor for multi-drug resistant HIV-1
-
Best B, Haubrich R. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. Exper Opin Invest Drugs. 2006;15(1):59-70.
-
(2006)
Exper Opin Invest Drugs
, vol.15
, Issue.1
, pp. 59-70
-
-
Best, B.1
Haubrich, R.2
-
14
-
-
0038576281
-
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
-
Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
-
(2003)
N Engl J Med
, vol.348
, pp. 2175-2185
-
-
Lalezari, J.P.1
Henry, K.2
O'Hearn, M.3
-
15
-
-
0037849954
-
Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia
-
Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
-
(2003)
N Engl J Med
, vol.348
, pp. 2186-2195
-
-
Lazzarin, A.1
Clotet, B.2
Cooper, D.3
-
16
-
-
0141609130
-
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial
-
Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139(5 pt 1):313-320.
-
(2003)
Ann Intern Med
, vol.139
, Issue.5 PART 1
, pp. 313-320
-
-
Squires, K.1
Pozniak, A.L.2
Pierone, G.3
-
17
-
-
0034069732
-
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomised, double-blind trial
-
Katlama C, Clotet B, Plettenberg A, et al. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomised, double-blind trial. AIDS. 2000;14:781-789.
-
(2000)
AIDS
, vol.14
, pp. 781-789
-
-
Katlama, C.1
Clotet, B.2
Plettenberg, A.3
-
18
-
-
0030997937
-
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
-
CAESAR Coordinating Committee
-
CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349(9063):1413-1421.
-
(1997)
Lancet
, vol.349
, Issue.9063
, pp. 1413-1421
-
-
-
19
-
-
34547172889
-
-
Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, Colorado, USA. Abstract 537.
-
Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, Colorado, USA. Abstract 537.
-
-
-
-
20
-
-
33645058159
-
Distribution of health-care expenditures for HIV-infected patients
-
Chen R, Accortt, N, Westfall A, et al. Distribution of health-care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1002-1010.
-
(2006)
Clin Infect Dis
, vol.42
, pp. 1002-1010
-
-
Chen, R.1
Accortt, N.2
Westfall, A.3
-
21
-
-
3042740596
-
Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes
-
Ledergerber B, Lundgren J, Walker A, et al. Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
-
(2004)
Lancet
, vol.364
, pp. 51-62
-
-
Ledergerber, B.1
Lundgren, J.2
Walker, A.3
-
22
-
-
34547217640
-
-
Benzie A, Bansi L, Sabin C, Walsh J, Phillips A. Viral rebound in patients on HAART with viral suppression. Presented at the BHIVA Spring Conference; April 2006; Brighton, UK [abstract 09]. HIV Med. 2006;7(suppl 1):1-9.
-
Benzie A, Bansi L, Sabin C, Walsh J, Phillips A. Viral rebound in patients on HAART with viral suppression. Presented at the BHIVA Spring Conference; April 2006; Brighton, UK [abstract 09]. HIV Med. 2006;7(suppl 1):1-9.
-
-
-
-
23
-
-
34547228421
-
-
DeMasi R, Thommes J, Graham N. Currently marketed nucleosides provide only marginal additional viral load (VL) suppression to regimens including enfuvirtide (ENF) and boosted Pis (PI/r) in triple class experienced patients. In: Program and abstracts of the XVI International AIDS Conference; August 2006; Toronto, Canada. Abstract THPE0125.
-
DeMasi R, Thommes J, Graham N. Currently marketed nucleosides provide only marginal additional viral load (VL) suppression to regimens including enfuvirtide (ENF) and boosted Pis (PI/r) in triple class experienced patients. In: Program and abstracts of the XVI International AIDS Conference; August 2006; Toronto, Canada. Abstract THPE0125.
-
-
-
-
24
-
-
33748028822
-
Initial treatment of HIV infection: Randomized trials with clinical end points are still needed
-
Hughes MD. Initial treatment of HIV infection: randomized trials with clinical end points are still needed. J Infect Dis. 2006;194:542-544.
-
(2006)
J Infect Dis
, vol.194
, pp. 542-544
-
-
Hughes, M.D.1
-
25
-
-
33846490256
-
Cost to achieve an undetectable viral load using recommended antiretroviral regimens
-
Basu RP, Grimes RM, Helmy A. Cost to achieve an undetectable viral load using recommended antiretroviral regimens. HIV Clin Trials. 2006;7:309-318.
-
(2006)
HIV Clin Trials
, vol.7
, pp. 309-318
-
-
Basu, R.P.1
Grimes, R.M.2
Helmy, A.3
|